Skip to main content
Book cover

Biomarkers for Preclinical Alzheimer’s Disease

  • Book
  • © 2018

Overview

  • Includes cutting-edge methods and protocols
  • Provides step-by-step detail essential for reproducible results
  • Contains key notes and implementation advice from the experts

Part of the book series: Neuromethods (NM, volume 137)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 119.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (18 protocols)

  1. Alzheimer’s Disease as a Societal Challenge

  2. Diagnostic Concepts

  3. Established Markers of Pathophysiology and Risk

  4. Biomarker Discovery

Keywords

About this book

This volume discusses the importance of imaging, fluid, and genetic biomarkers in detecting the earliest pre-symptomatic stages of Alzheimer’s disease (AD). The chapters in this book are separated into five parts. Part one explores the reasons why we need improved approaches for early detection and diagnosis of AD. Part two describes clinical and research techniques for preclinical AD diagnosis. Part three looks at the current methods in use to diagnose AD and how they can also be used for early detection in healthy older individuals. Parts four and five talk about technological advancements in AD diagnosis and ethical considerations in AD research. In Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.

Comprehensive and cutting-edge, Biomarkers for Preclinical Alzheimer’s Disease is a valuable resource for individuals interested in the use of biomarker strategies to improve early AD detection. This book will be of great interest to researchers and clinicians from both academia and industry.”



Editors and Affiliations

  • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany

    Robert Perneczky

Bibliographic Information

  • Book Title: Biomarkers for Preclinical Alzheimer’s Disease

  • Editors: Robert Perneczky

  • Series Title: Neuromethods

  • DOI: https://doi.org/10.1007/978-1-4939-7674-4

  • Publisher: Humana New York, NY

  • eBook Packages: Springer Protocols

  • Copyright Information: Springer Science+Business Media, LLC 2018

  • Hardcover ISBN: 978-1-4939-7673-7Published: 27 February 2018

  • Softcover ISBN: 978-1-4939-9255-3Published: 10 December 2019

  • eBook ISBN: 978-1-4939-7674-4Published: 26 February 2018

  • Series ISSN: 0893-2336

  • Series E-ISSN: 1940-6045

  • Edition Number: 1

  • Number of Pages: XIII, 272

  • Number of Illustrations: 6 b/w illustrations, 33 illustrations in colour

  • Topics: Neurosciences

Publish with us